Engine Biosciences获得2700万美元A轮融资，以推进精准肿瘤药物和患者选择的新型生物标记物开发-动脉网

Engine Biosciences Secures $27 Million Series A Extension to Advance Development of Precision Oncology Medicines and Novel Biomarkers for Patient Selection

BioSpace 等信源发布 2023-11-01 05:20



可切换为仅中文







Backed by existing and new domain expert investors, extension brings Series A total to $70 Million, and total funds raised to date to $86 Million

在现有和新领域专家投资者的支持下，延期使A系列产品总计达到7000万美元，迄今为止筹集的资金总额达到8600万美元

Funds to support translation of R&D programs derived from proprietary NetMAPPR machine learning network biology platform and CombiGEM combinatorial genetics system into clinical settings

支持将专有NetMAPPR机器学习网络生物学平台和CombiGEM组合遗传学系统衍生的研发项目转化为临床环境的资金

SINGAPORE & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Engine Biosciences, a company leveraging machine learning and high-throughput biology to discover and develop precision oncology medicines, today announced the completion of a $27 million Series A extension. The financing was led by Polaris Partners, with participation from both new and existing investors, bringing the total funds raised since inception to $86 million.

新加坡和加利福尼亚州红木城（BUSINESS WIRE）-Engine Biosciences是一家利用机器学习和高通量生物学发现和开发精密肿瘤药物的公司，今天宣布完成2700万美元的a系列延期。这项融资由北极星合作伙伴领导，新投资者和现有投资者都参与其中，使自成立以来筹集的资金总额达到8600万美元。

Additional participating investors include existing investors ClavystBio (a life sciences venture investor set up by Temasek), Invus, and Singapore-based global investor EDBI, as well as new investors Coronet Ventures (a Singapore-based investment entity of Cedars Sinai Intellectual Property Company) and SEEDS Capital (investment arm of Enterprise Singapore).

其他参与投资者包括现有投资者ClavystBio（由Temasek成立的生命科学风险投资者），Invus和新加坡的全球投资者EDBI，以及新投资者Coronet Ventures（Cedars-Sinai知识产权的新加坡投资实体）公司）和种子资本（新加坡企业投资部门）。

In conjunction with the financing, Wen Qi Ho Ph.D., Therapeutics Lead at ClavystBio, joined Engine’s Board of Directors..

在融资的同时，ClavystBio的Therapeutics领导何文琦博士加入了Engine的董事会。。

Engine’s precision medicine R&D platform deciphers biological networks and pinpoints key genetic interactions driving diseases, overcoming challenges presented by biological complexity. These insights reveal targets and therapeutics to be used in biomarker-defined patient populations, allowing for more rapid identification of effective precision medicines.

引擎的精准医学研发平台破译生物网络并查明驱动疾病的关键遗传相互作用，克服生物复杂性带来的挑战。这些见解揭示了用于生物标志物定义的患者群体的靶标和治疗剂，允许更快速地鉴定有效的精确药物。

In oncology, Engine leverages the validated principle of synthetic lethality and is focused on the clinical translation of therapeutics and biomarkers across solid tumors, including ovarian, colorectal, liver, lung and prostate cancers..

在肿瘤学领域，Engine利用经过验证的合成致死原理，专注于实体瘤（包括卵巢癌，结肠直肠癌，肝癌，肺癌和前列腺癌）的治疗和生物标志物的临床翻译。。

“Our findings support Engine’s mission to deliver clinical impact through directing the right drug for the right target to the right patient,” said Jeffrey Lu, Engine Biosciences’ Co-Founder and CEO. “We appreciate the confidence of both existing and new investors demonstrated through this financing, as we continue steadfast in our goals to drive clinical translation of our insights, internally and with partners.”.

Engine Biosciences的联合创始人兼首席执行官Jeffrey Lu说：“我们的研究结果支持Engine的使命，即通过将正确目标的正确药物导向正确的患者来提供临床影响。“我们感谢通过此次融资证明的现有和新投资者的信心，因为我们继续坚定地实现我们的目标，推动我们的见解，内部和合作伙伴的临床翻译。”。

Engine has revealed over thirty previously unidentified precision medicine opportunities with validation data, anchoring its pipeline and feeding partnerships. Its internal drug discovery biology and chemistry teams have progressed multiple programs significantly from initial identification. Among its oncology pipeline is ENB-812, which Engine has overseen from independently discovering PKMYT1 as a synthetic lethal target with novel biomarkers in 2019, generating robust preclinical proof-of-concept across many tumor types and animal models, observing supportive clinical data, and advancing lead identification and optimization..

Engine已经揭示了超过30个以前未确定的精准医学机会，其中包括验证数据，锚定其管道和喂养伙伴关系。其内部药物发现生物学和化学团队从最初的鉴定中已经取得了重大进展。其肿瘤学管道包括ENB-812，该引擎负责监督2019年独立发现PKMYT1作为具有新型生物标志物的合成致死靶标，在许多肿瘤类型和动物模型中产生强大的临床前概念验证，观察支持性临床数据，以及推进领导识别和优化。。

In addition to high-value targets and drug candidates, Engine identified new patient selection biomarkers for several distinct classes of targeted therapies. Engine’s biomarkers have been validated to sensitize tumors by 100 times to specific clinical-stage investigational drugs. These biomarkers present near-term potential to enhance clinical outcomes, increase commercial potential, and improve drug development economics..

除了高价值目标和候选药物外，Engine还为几种不同类别的靶向治疗确定了新的患者选择生物标志物。引擎的生物标志物已经过验证，可以使肿瘤对特定的临床阶段研究药物敏感100倍。这些生物标志物具有提高临床结果，增加商业潜力和改善药物开发经济性的近期潜力。。

“We have witnessed first-hand Engine’s considerable progress since our initial investment, advancing its technologies towards compelling precision medicines positioned for translation,” said Amy Schulman, Managing Partner of Polaris Partners. “We are excited to lead this strong investor syndicate in support of Engine’s pursuit of clinical value creation through development of its therapeutics and biomarkers and partnerships.”.

Polaris合作伙伴的合作伙伴艾米·舒尔曼（Amy Schulman）说：“自从我们最初的投资以来，我们目睹了第一手引擎的巨大进步，将其技术推向了引人注目的精准药物翻译。“我们很高兴带领这个强大的投资者集团，通过开发其治疗方法，生物标志物和合作伙伴关系，支持Engine追求临床价值创造。”。

Benefiting from several years of research and development in its Singapore and Silicon Valley sites and foundational science from MIT, UCSF, UCSD, and Mayo Clinic, Engine’s proprietary platforms, NetMAPPR (machine learning-enabled network biology) and CombiGEM (combinatorial genetics experimentation), are engineered for drug hunters and clinical developers to discover and optimize precision medicines.

得益于新加坡和山谷地区多年的研究和开发以及麻省理工学院，UCSF，UCSD和Mayo Clinic的基础科学，Engine的专有平台NetMAPPR（机器学习启用的网络生物学）和CombiGEM（组合遗传学实验），为药物猎人和临床开发商设计，以发现和优化精准药物。

In addition to high-value targets with associated biomarker-defined patient populations, Engine’s extensive biology knowledge and datasets provide insights on desirable target product profile characteristics, guiding design and optimization of first-in-class and best-in-class therapeutics..

除了具有相关生物标志物定义的患者群体的高价值目标之外，Engine广泛的生物学知识和数据集还提供了有关理想目标产品概况特征的见解，指导一流和一流疗法的设计和优化。。

“We are excited about supporting Engine’s growth as a global biotech company, with a strong syndicate of life sciences investors,” said Wen Qi Ho, Ph.D., Therapeutics Lead, ClavystBio. “This is consistent with our mission to translate breakthrough research into clinical impact, and build ventures in Singapore with access to talent, data and clinical opportunities internationally.”.

ClavystBio治疗公司负责人Wen-Qi Ho博士说：“我们对支持Engine作为全球生物技术公司的成长感到兴奋，该公司拥有强大的生命科学投资者集团。“这符合我们将突破性研究转化为临床影响的使命，并在新加坡建立企业，获得国际人才，数据和临床机会。”。

Engine’s programs and platform are underpinned by an extensive patent portfolio. With the additional funds secured, Engine will further advance its biomarker and target discoveries toward the clinic through internal development, collaborations, and partnerships.

发动机的计划和平台以广泛的专利组合为基础。在获得额外资金的情况下，Engine将通过内部开发，合作和合作关系进一步推进其生物标志物和目标发现。

“Precision medicine holds the key to the next wave of groundbreaking treatments, a belief that ties Coronet Ventures closely with Engine's mission,” said Nirdesh Gupta, Ph.D., CEO of Coronet Ventures. “Investing in Engine Biosciences reflects our commitments to bringing research breakthroughs to clinical fruition, and anchoring ventures in Singapore that are primed for global success.”.

Coronet Ventures首席执行官Nirdesh Gupta博士说：“精准医学是下一波开创性治疗的关键，这种信念认为Coronet Ventures与Engine的使命密切相关。“投资发动机生物科学反映了我们为临床成果带来研究突破的承诺，以及为全球成功做好准备的新加坡企业。

About NetMAPPR and CombiGEM

关于NetMAPPR和CombiGEM

NetMAPPR, Engine’s biology search platform, maps biological networks and reveals critical genetic and molecular interactions integral to diseases. Over the past six years, NetMAPPR has been rigorously engineered and trained by machine learning and internal experimentation feedback loops, together with the largest-known oncology gene interaction and synthetic lethality knowledge base.

NetMAPPR是引擎的生物学搜索平台，可绘制生物网络图并揭示疾病中不可或缺的关键遗传和分子相互作用。在过去的六年中，NetMAPPR通过机器学习和内部实验反馈回路以及最大的已知肿瘤基因相互作用和合成致死性知识库进行了严格的设计和培训。

Engine’s databases comprise of proprietary functional genomics data generated in-house, clinical data including through extensive relationships with hospitals, and AI-enhanced literature mining. Engine’s CombiGEM combinatorial CRISPR platform delivers masses of purpose-built experimental data to enhance NetMAPPR and validate findings for drug development.

Engine的数据库包括内部生成的专有功能基因组学数据，包括通过与医院的广泛关系在内的临床数据以及AI增强的文献挖掘。Engine的CombiGEM组合CRISPR平台提供大量专用实验数据，以增强NetMAPPR并验证药物开发的结果。

Together, these technologies inform Engine’s growing pipeline of potential high-impact therapeutics, targets, and patient selection biomarkers to support drug development and partners in oncology and additional disease areas..

这些技术共同为Engine不断增长的潜在高影响力治疗，靶点和患者选择生物标志物管道提供支持，以支持肿瘤和其他疾病领域的药物开发和合作伙伴。。

About Engine Biosciences

关于发动机生物科学

Engine Biosciences is a venture-backed Singapore and Silicon Valley based company discovering and developing impactful precision medicines by deciphering complex biology with integrated computation and experimentation, with particular depth in oncology gained over several years of substantial investment and focus.

Engine Biosciences是一家由风险支持的新加坡和山谷公司，通过综合计算和实验破译复杂的生物学，发现和开发有影响力的精密药物，经过多年的大量投资和关注，在肿瘤学方面获得了特别的深度。

Having pinpointed many promising drug targets and predictive biomarkers for patients most likely to benefit, Engine is advancing its pipeline of oncology therapeutics towards the clinic internally and with collaborators, and in other disease areas through partnerships. Engine’s team is motivated by opportunities to address significant unmet needs with more selective and effective precision medicines.

已经为最有可能受益的患者确定了许多有希望的药物靶标和预测性生物标志物，Engine正在通过合作伙伴关系将其肿瘤学治疗管道内部和合作者以及其他疾病领域推进到临床。引擎团队的动力来自于通过更具选择性和有效的精密药物解决重大未满足需求的机会。

For more information, please visit www.enginebio.com, and follow Engine on LinkedIn..

欲了解更多信息，请访问www.enginebio.com，并按照LinkedIn上的引擎操作。。

View source version on businesswire.com: https://www.businesswire.com/news/home/20231031910592/en/

在businesswire.com上查看源版本：https://www.businesswire.com/news/home/20231031910592/en/

Contacts

联络

Media Contacts:

媒体联系人：

For U.S. office:

对于美国办事处：

Cassidy McClain